Research chemicalResearch chemicalPhenethylaminePsychedelic
3C-P
Also known as 3C-Proscaline · 1-(3-propoxy-4,5-dimethoxyphenyl)propan-2-amine
3C-P is a psychedelic phenethylamine, the alpha-methylated homologue of proscaline and a higher homologue of 3C-E. It is potent and long-acting with a strongly visual profile, and is among the least-studied scalines.
01 Overview
3C-P adds an alpha-methyl group to proscaline. It is reported as potent, deeply visual and long in duration, extending the 3C-E pattern with a propoxy chain.
Human evidence is minimal and anecdotal. As one of the more obscure scalines, its dose-response and safety profile are very poorly characterised, and it is highly dose-sensitive.
02 Mechanism
Serotonin 5-HT2A receptor agonist; alpha-methylation and the propoxy group together confer high potency.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 5–15 mg | Oral | |
| Common | 15–40 mg | Oral | Anecdotal range. |
| Strong | 40–60 mg | Oral |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Strong visualsProminent visual patterning and colour. | Anecdotal | ||
| Psychedelic headspaceDeep cognitive alteration over a long course. | Anecdotal | ||
| Long durationVery extended experience. | 9-14 h | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NauseaOnset queasiness. | Mild | Common | Anecdotal | |
| Sympathomimetic stimulationPresumed cardiovascular stimulation. | Mild | Common | Unconfirmed | |
| AnxietyAnxiety or difficult experiences at higher doses. | Moderate | Dose-dependent | Anecdotal |
06 Legal status
United Kingdom
Class A
as of Jan 2026
United States
Unscheduled
Possible Analogue Act coverage. · as of Jan 2026
07 References
3C-P entryIsomer Design / community pharmacology summaries
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.